Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Q1 2025 Earnings Presentation
25 slides from Cytosorbents's earnings presentation, May 14, 2025
Slide 1: Q1 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation Nasdaq: CTSO Q1 2025 Financial Results and Recent Business Highlights Conference Call May 14, 2025
Slide 2: Conference Call Participants
Conference Call Participants Moderator: Adanna Alexander, PhD Phillip Chan, MD, PhD VP Investor Relations, ICR Chief Executive Officer Healthcare Efthymios “Makis” Deliargyris MD, FACC, FESC, FSCAI Chief Medical Officer Peter J. Mariani, CPA Chief Financial Officer 2
Slide 3: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actu
Slide 4: Operational Update
Operational Update Phillip Chan, MD, PhD Chief Executive Officer 4
Slide 5: CytoSorbents at a Glance
CytoSorbents at a Glance • Platform blood purification technology for removing toxins and harmful substances from the blood • High margin “razorblade” that is “plug and play” into existing hospital blood pumps • Two main products leveraging the underlying polymer technology CytoSorb • Treatment of l
Slide 6: Agenda
Agenda • Core CytoSorb Sales • Regulatory/Clinical Update on DrugSorb-ATR • Operating metrics and cash 6
Slide 7: CytoSorb Update
CytoSorb Update CytoSorbents.
Slide 8: Q1 2025 Sales Overview
Q1 2025 Sales Overview • Q1 2025 Product Sales were $8.7M, a 3% decrease y-o-y. On a constant currency basis, sales were flat • Strong performance from International Distribution and Other Direct Sales countries significantly offset disruption in German Direct Sales caused by our proactive reorganiz
Slide 9: CytoSorb Integrated Approach for Critical Care
CytoSorb Integrated Approach for Critical Care Myoglobin Right Break the Patient Cycle of Deadly Bilirubin Inflammation Free hemoglobin Highest Chance for Reverse Good Instability Overdose Clinical drugs Outcome Right Right Digestive Timing Dose enzymes Restore and Preserve Organ Many Function Other
Slide 10: CytoSorb - The Antibiotic Analogy
CytoSorb - The Antibiotic Analogy Right Patient • Treat Early Highest Chance for • Treat Aggressively Good Clinical • Compete the full course of treatment Outcome Right Right Timing Dose 10
Slide 11: Key Catalysts for Future Growth
Key Catalysts for Future Growth • Compelling new data in core applications • New, simplified and impactful messaging to customers • Return Germany to growth through optimization of German commercial team and sales approach • Geographic expansion with Dubai, UAE subsidiary – Gateway to Middle East an
Slide 12: Update
Dr. Phillip Chan Update Chief Executive Officer Dr. Efthymios Deliargyris Chief Medical Officer 12
Slide 13: Blood Thinners Can Cause Serious Perioperative Bleeding
Blood Thinners Can Cause Serious Perioperative Bleeding DrugSorb-ATR can help • Acute heart attack patients commonly receive blood thinners like Brilinta® to improve clinical outcomes • But Brilinta® (ticagrelor) can cause serious and potentially life-threatening bleeding in patients that need to un
Slide 14: FDA and Health Canada Regulatory Update
FDA and Health Canada Regulatory Update • FDA De Novo submission and Medical Device License application to Health Canada included STAR-T RCT data and STAR registry real world evidence (RWE) • Interactive review with FDA resolved many issues, however, a denial letter was issued April 25, 2025 • Subse
Slide 15: Real World Evidence
Real World Evidence • STAR Registry now in 6 countries (GER, UK, BEL, AUT, SWE, CH) with 600+ subjects enrolled in different cardiac surgeries • Ticagrelor removal in 102 CABG patients now published • Ticagrelor removal in 150 CABG patients to be presented in Paris at EuroPCR next week • First repor
Slide 16: Preparing for Potential Launch
Preparing for Potential Launch • Preparing for a controlled market release as we wait for FDA and Health Canada decisions • Get real-world feedback • Validate assumptions • Refine our commercialization strategy • DrugSorb-ATR Launch Team is undertaking a number pre-launch activities • Engaging with
Slide 17: Introducing Tom Shannon – VP Marketing, North America
Introducing Tom Shannon – VP Marketing, North America Tom Shannon Vice President Marketing, North America • Genesee Biomedical - VP of Sales and Marketing, an innovator in cardiac heart valve repair • Fresenius Medical Care - Director of Marketing. Launched the first FDA-cleared ECMO machine • Getin
Slide 18: Financial Highlights
Financial Highlights Peter J. Mariani Chief Financial Officer 18
Slide 19: Revenue and Gross Margin
Revenue and Gross Margin • Strength in other our Distributor and other EU Direct Markets offset by declines in 1Q25 1Q24 YoY Change Germany • We are pleased with the progress of our initiative to realign our commercial team and Revenue $8.7m $9.0m -3% sales approach in Germany and expect Constant cu
Slide 20: Improved Operating Leverage
Improved Operating Leverage 1Q25 1Q24 YoY Change Total operating expenses $10.1m $11.5m 12% decrease Operating loss $3.9m $4.7m 17% improvement Net loss $1.5m / $0.02/sh $6.1 m / $0.11/sh Adjusted net loss $3.7m / $0.06/sh $3.7m / $0.07/sh Adjusted EBITDA loss $2.7m $3.3m 17% improvement *Non-GAAP m
Slide 21: Strengthened balance sheet
Strengthened balance sheet Driving core business to cash flow break-even in 2H 2025 • $6.8 million received from successful Rights Offering • Provided $6.8 million, net of fees, to date • Released $5.0 million of restricted cash • Together increased net liquidity of $11.8 million • 60-day extension
Slide 22: Introducing Melanie Grossman – VP and Controller
Introducing Melanie Grossman– VP and Controller • Over 25 years of accomplished finance and accounting leadership in global, publicly-traded, and private companies • SEC reporting, financial systems, processes and internal controls • Financial planning, analysis and strategy • Former Ernst & Young (
Slide 23: Closing Remarks
Closing Remarks Phillip Chan, MD, PhD Chief Executive Officer 23
Slide 24: A Clear and Compelling Value Proposition
A Clear and Compelling Value Proposition CytoSorb is an established, international core business in critical care and cardiac surgery with $35M+ in high margin product sales with expectations for growth due to: • Significant market opportunity, targeting major unmet medical needs • “Right patient at
Slide 25: Q&A Session
Q&A Session NASDAQ: CTSO Company Contact: Dr. Phillip Chan pchan@cytosorbents.com Investor Relations Contact: Aman Patel, CFA & Adanna Alexander, PhD ICR Healthcare ir@cytosorbents.com 25